Drug Trial Radar · NCT00395460
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
Last checked: Nov 20, 2026Latest source record: Jun 8, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Sep 2006
Primary completion
Apr 2007
Study completion Apr 2007
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Nov 3, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.
Conditions
- Central Nervous System Diseases
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug
1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
MagnevistDrug
0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Contrast to Noise Ratio (CNR) Between Pre- and Post-contrast Magnetic Resonance Imaging (MRI) Scan of Central Nervous System (CNS) LesionsTime frame: Immediately before injection (pre-contrast) and 2-5 min after injection (post-contrast)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hosp.
Beijing, China
Fudan University Huashan Hospital
Shanghai, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The 1st Affiliated Hosp of the 4th Military Med Uni
Xi'an, Shaanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.